Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zelicapavir - Enanta Pharmaceuticals

Next Previous
Drug Profile

Zelicapavir - Enanta Pharmaceuticals

Alternative Names: EDP-938; EP 023938

Latest Information Update: 23 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Enanta Pharmaceuticals
  • Class Amines; Antivirals; Benzene derivatives; Benzodiazepines; Fluorocarbons; Ketones; Morpholines; Oxadiazoles; Pyridines; Small molecules
  • Mechanism of Action Nucleoprotein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Respiratory syncytial virus infections

Most Recent Events

  • 09 Jul 2026 Phase-II clinical trials in Respiratory syncytial virus infections (In neonates, In infants, In children) in Thailand (PO) (NCT07482657)
  • 18 Jun 2026 US FDA held a End-of-Phase 2 meeting with the Enanta Pharmaceuticals for phase IIB/III trial for Respiratory syncytial virus infections
  • 06 May 2026 Enanta Pharmaceuticals plans a phase IIb/III RESOLVE trial for Respiratory syncytial virus infections in fourth quarter of 2026

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top